TY - JOUR T1 - Mitogen-activated protein kinase inhibitor-associated retinopathy (MEKAR). A clinical case JO - Archivos de la Sociedad Española de Oftalmología (English Edition) T2 - AU - Buenasmañanas-Maeso,M. AU - Gutiérrez-Montero,Ó. AU - Reche-Sainz,J.A. AU - Badillo Arcones,E. AU - Monja-Alarcón,N. AU - Toledano-Fernández,N. SN - 21735794 M3 - 10.1016/j.oftale.2022.02.006 DO - 10.1016/j.oftale.2022.02.006 UR - https://www.elsevier.es/en-revista-archivos-sociedad-espanola-oftalmologia-english-496-articulo-mitogen-activated-protein-kinase-inhibitor-associated-retinopathy-S2173579422000263 AB - Mitogen-activated protein kinase kinase (MEK) inhibitors have significantly improved the prognosis of various types of cancer such as metastatic melanoma. However, their use is usually associated with ocular side effects. A retinopathy associated with these agents (MEKAR) has been described, consisting of the development of neurosensory detachments, generally bilateral and multiple, similar to those that appear in the central serous chorioretinopathy (CSC). Generally, optical coherence tomography allows us to differentiate the two conditions. We present the case of a 55-year-old woman in treatment with a MEK inhibitor, who developed bilateral neurosensory detachments and blurred vision, which resolved with the discontinuance of the treatment due to tumour progression. ER -